Добірка наукової літератури з теми "Vaccine candidate protein"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Vaccine candidate protein".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Vaccine candidate protein"
Panda, Chinmaya, and Rajani Kanta Mahapatra. "Identification of novel therapeutic candidates inCryptosporidium parvum: anin silicoapproach." Parasitology 145, no. 14 (April 25, 2018): 1907–16. http://dx.doi.org/10.1017/s0031182018000677.
Повний текст джерелаZeb, Samia, Amjad Ali, Sardar Muhammad Gulfam, and Habib Bokhari. "Preliminary Work Towards Finding Proteins as Potential Vaccine Candidates for Vibrio cholerae Pakistani Isolates through Reverse Vaccinology." Medicina 55, no. 5 (May 23, 2019): 195. http://dx.doi.org/10.3390/medicina55050195.
Повний текст джерелаTumban, Ebenezer. "Lead SARS-CoV-2 Candidate Vaccines: Expectations from Phase III Trials and Recommendations Post-Vaccine Approval." Viruses 13, no. 1 (December 31, 2020): 54. http://dx.doi.org/10.3390/v13010054.
Повний текст джерелаMayers, Carl, Melanie Duffield, Sonya Rowe, Julie Miller, Bryan Lingard, Sarah Hayward, and Richard W. Titball. "Analysis of Known Bacterial Protein Vaccine Antigens Reveals Biased Physical Properties and Amino Acid Composition." Comparative and Functional Genomics 4, no. 5 (2003): 468–78. http://dx.doi.org/10.1002/cfg.319.
Повний текст джерелаGarcía-Basteiro, Alberto L., Quique Bassat, and Pedro L. Alonso. "APPROACHING THE TARGET: THE PATH TOWARDS AN EFFECTIVE MALARIA VACCINE." Mediterranean Journal of Hematology and Infectious Diseases 4, no. 1 (March 10, 2012): e2012015. http://dx.doi.org/10.4084/mjhid.2012.015.
Повний текст джерелаvan Doremalen, Neeltje, Robert J. Fischer, Jonathan E. Schulz, Myndi G. Holbrook, Brian J. Smith, Jamie Lovaglio, Benjamin Petsch, and Vincent J. Munster. "Immunogenicity of Low-Dose Prime-Boost Vaccination of mRNA Vaccine CV07050101 in Non-Human Primates." Viruses 13, no. 8 (August 19, 2021): 1645. http://dx.doi.org/10.3390/v13081645.
Повний текст джерелаLoo, Ke-Yan, Vengadesh Letchumanan, Hooi-Leng Ser, Siew Li Teoh, Jodi Woan-Fei Law, Loh Teng-Hern Tan, Nurul-Syakima Ab Mutalib, Kok-Gan Chan, and Learn-Han Lee. "COVID-19: Insights into Potential Vaccines." Microorganisms 9, no. 3 (March 15, 2021): 605. http://dx.doi.org/10.3390/microorganisms9030605.
Повний текст джерелаWainwright, Eleanor, and Rebecca K. Shears. "Trichuris WAP and CAP proteins: Potential whipworm vaccine candidates?" PLOS Neglected Tropical Diseases 16, no. 12 (December 22, 2022): e0010933. http://dx.doi.org/10.1371/journal.pntd.0010933.
Повний текст джерелаSchautteet, Katelijn, Edith Stuyven, Eric Cox, and Daisy Vanrompay. "Validation of the Chlamydia trachomatis genital challenge pig model for testing recombinant protein vaccines." Journal of Medical Microbiology 60, no. 1 (January 1, 2011): 117–27. http://dx.doi.org/10.1099/jmm.0.024448-0.
Повний текст джерелаWattimena, Mauritz Nicolaas, and Wijanarka Wijanarka. "In Silico Analysis Prediction of B-Cell Epitope as a Vaccine Candidate for SARS-CoV-2 B.1.617.2 (Delta) Variant." Journal of Biomedicine and Translational Research 1, no. 1 (March 8, 2022): 7–15. http://dx.doi.org/10.14710/jbtr.v1i1.13113.
Повний текст джерелаДисертації з теми "Vaccine candidate protein"
Sikora, Christopher A., and University of Lethbridge Faculty of Arts and Science. "Identification of a vaccine candidate in protein extracts from francisella tularensis." Thesis, Lethbridge, AB : University of Lethbridge, Faculty of Arts and Science, 2003, 2003. http://hdl.handle.net/10133/235.
Повний текст джерелаxii, 97 leaves ; 29 cm.
Koivula, Therese. "Production and characterisation of a chlamydial antigen candidate for vaccine trials." Thesis, Uppsala universitet, Molekylär biomimetik, 2021. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-451976.
Повний текст джерелаKreida, Stefan. "Chimeric MOMP : Expression of a Chlamydia Vaccine Candidate in Arabidopsis thaliana and Escherichia coli." Thesis, Örebro universitet, Akademin för naturvetenskap och teknik, 2011. http://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-20113.
Повний текст джерелаWright, Judith Claire. "Studies on the porB gene of Neisseria meningitidis : use as an epidemiological marker and as a potential vaccine candidate." Thesis, University of Southampton, 2000. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.323956.
Повний текст джерелаGuevara-Patino, Jose Alejandro. "Antibody responses to and the structure of plasmodium falciparum merozoite surface protein-1 : a candidate malaria vaccine antigen." Thesis, University College London (University of London), 1998. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.300163.
Повний текст джерелаGonzález, Zabala Juliana. "Conserved hemagglutinin peptides of influenza virus as potential multivalent vaccine candidate: characterization of immune response in different animal models." Doctoral thesis, Universitat Autònoma de Barcelona, 2016. http://hdl.handle.net/10803/384602.
Повний текст джерелаInfluenza A viruses (IAVs) are responsible for pandemic outbreaks of influenza, and for most of the well-known annual flu epidemics, in humans, poultry and pigs. IAVs are divided into subtypes, based on the nature of their surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA). The HA is a homotrimeric surface glycoprotein that mediates influenza viral entry via cellular attachment and membrane fusion events. The receptor-binding pocket of HA is surrounded by antigenically variable antibody binding sites. Therefore, antibodies bounded to these sites should, in principle, block the binding to receptor proteins, inhibiting viral entry, demonstrating hemagglutinin inhibition activity and viral neutralization activity. However, the subunit 1 of HA (HA1) is highly variable across viruses and tends to change under immune pressure and, hence, easily evades the neutralizing antibodies induced by previous vaccinations or infections. The negative implications of influenza virus infections push the world to promote the development of multivalent flu vaccines that protect against all human influenza strains. Therefore, the field of bioinformatics has become a major part of the identification and early validation of new therapeutic targets and could be an essential first step in the development of an effective vaccine for influenza virus that represents the high variability of its antigenic determinants. Therefore, in this thesis it was postulated that the HA1 could represent a potential target for a multivalent vaccine of influenza infection. Consequently, the general objective of this thesis was to select conserved peptides from the HA1 of influenza viruses and to evaluate the efficacy of the selected candidates to induce immunity that can protect animal against infection. To achieve this objective, three studies were undertaken in mice (Chapter 1), pigs (chapter 2) and chickens (Chapter 3). In the first study, we evaluated the protective effect of improved HA1-peptides against the pandemic H1N1 2009 virus and a H7N1 highly pathogenic influenza virus (HPAIV) in a mouse model (Chapter 1). In this study, mice were intraperitoneally vaccinated with the peptide mix (NG34+DC89), and next challenged with either the pH1N1 or the H7N1 strain of Influenza virus. Conversely to the 85% mortality observed in control mice, independently of the virus used for challenge, 80% and 66% of the peptide-vaccinated mice survived the challenge with pH1N1 and H7N1, respectively, without detection of influenza viruses (IV). Vaccinated mice surviving correlated with the presence of cross-reactive neutralizing antibodies in sera prior to challenge. The immunization with NG34+DC89 also induced mucosal immune responses demonstrated with the presence of IgA in bronchoalveolar lavage in 50% of the animals. Our results also show that NG34+DC89 is capable to induce cross-neutralizing antibodies and protection against two heterologous IV, pH1N1 and H7N1. Thus, NG34+DC89 represent an attractive immunogen, which could be further optimized for future multivalent vaccine formulations against influenza virus. In the second study, we tested the immunogenicity of a HA1-peptide cocktail in a pig model to assess whether this new formulation can confer immunity to a wide range of IAVs in vitro (Chapter 2). Four peptides (NG34, DC55, RA22 and SS35) within the HA1 from H1 viruses were selected, and evaluated their immunogenicity in conventional farm pigs against homologous and heterologous viruses of influenza. Peptides immunizations induced HA neutralizing and inhibiting antibodies against homologous viruses. Those also cross-reacted against heterologous viruses like H7N1 and H5N2 and, most importantly, the circulating H3N2. Moreover, secretory IgA-specific HA antibodies in nasal swabs were detected. Altogether, the results show that the peptides tested were immunogenic in pigs. The humoral response with hemagglutinin-inhibiting and cross-neutralizing activity generated after immunization could be used in further studies of protective heterosubtypic immunity. In the third study we evaluated the protective effect of improved HA1-peptides against H7N1 highly pathogenic influenza virus (HPAIV) in chickens, a natural host model (Chapter 3). In this study, based on ISM, we selected two highly conserved peptides (NG34 and SS35) of a H1 influenza virus strain and used them to vaccinate free-range chickens. The vaccination with both NG34 and SS35 peptides induced specific antibodies that recognized heterologous viruses, as H7N1 HPAIV and H5N2 Low pathogenic avian virus (LPAIV) in vitro. Vaccination with NG34 peptide elicited a protective antibody response that conferred partial protection against a lethal challenge with H7N1 HPAIV. Furthermore, NG34 peptide induced a mucosal immune response, which correlated with reduced viral shedding in oropharyngeal/cloacal swabs and feather pulp. On the contrary, SS35 peptide vaccinated animals failed to produce an efficient protective immune response as no survival against lethal H7N1 challenge was achieved. Finally, it remains to point out that all HA1-peptides from H1 subtype of influenza virus were selected by the method of informative spectra (ISM). Four main general conclusions can be drawn from these studies: (i) HA1-peptides are immunogenic in all the animals models tested (mice, pigs and chickens) and induce humoral and mucosal immune response. (ii) Novel conserved immunogenic peptides from the hemagglutinin subunit 1 protein of influenza viruses confer partial protection against different viral subtypes in mice; (iii) Pigs vaccinated with HA1 peptides elicit neutralizing and hemagglutination-inhibiting antibody responses against different subtypes of Influenza A virus and (iv) Synthetic peptides from the hemagglutinin of influenza viruses confer partial protection against highly pathogenic A/H7N1 virus in a free-range chicken model. Overall, these data provide insights on new approaches for vaccination in influenza and understanding of the immune response against influenza viruses in mice, pigs and chickens.
Tawfick, Abd Raboh Mahmoud Mohamed. "Characterisation of the Salmonella Stk fimbrial operon and examination of Stkf, the putative adhesion protein, as a potential diagnostic and vaccine candidate." Thesis, University of Leicester, 2012. http://hdl.handle.net/2381/11004.
Повний текст джерелаEgan, Andrea. "Human immune responses to the C-terminus of the malaria vaccine candidate antigen, the major merozoite surface protein of Plasmodium falciparum (PfMSP1)." Thesis, University of Edinburgh, 1995. http://hdl.handle.net/1842/13778.
Повний текст джерелаJäschke, Anja [Verfasser], and Michael [Akademischer Betreuer] Lanzer. "Analysis of the human immune response against the Merozoite Surface Protein (MSP)-1 from Plasmodium falciparum – a malaria vaccine candidate / Anja Jäschke ; Betreuer: Michael Lanzer." Heidelberg : Universitätsbibliothek Heidelberg, 2017. http://d-nb.info/1178010619/34.
Повний текст джерелаMacLean, James Malcolm. "Investigation of the use of recombinant BCG, expressing the major capsid protein (LI) of human papillomavirus type 16, as a candidate vaccine for cervical cancer." Doctoral thesis, University of Cape Town, 2005. http://hdl.handle.net/11427/2730.
Повний текст джерелаЧастини книг з теми "Vaccine candidate protein"
Raz, Abbasali, Mahdieh Manafi, and Mahdokht Ilbeigi Khamseh Nejad. "Molecular Characterization of a Vector-Based Candidate Antigen Using the 3′-RACE and and In Silico Analysis of the Correspondent Protein for and Development." In Vaccine Design, 567–79. New York, NY: Springer US, 2021. http://dx.doi.org/10.1007/978-1-0716-1884-4_29.
Повний текст джерелаMustafa, Abu Salim. "Mycobacterium w: Candidate Vaccine Against Leprosy with Antigens CrossReactive with Three Major Protein Antigens of Mycobacterium leprae." In Progress in Vaccinology, 323–33. New York, NY: Springer New York, 1989. http://dx.doi.org/10.1007/978-1-4612-3508-8_30.
Повний текст джерелаNilofer, Christina, Arumugam Mohanapriya, and Pandjassarame Kangueane. "HIV-1 Envelope (ENV) GP160 Trimer Protein Complex SPIKE as a Recombinant Macromolecular Assembly Vaccine Component Candidate: Current Opinion." In Global Virology II - HIV and NeuroAIDS, 939–51. New York, NY: Springer New York, 2017. http://dx.doi.org/10.1007/978-1-4939-7290-6_36.
Повний текст джерелаPan, Jianyi, Chuchu Li, and Zhicang Ye. "Immunoproteomic Approach for Screening Vaccine Candidates from Bacterial Outer Membrane Proteins." In Vaccine Design, 519–28. New York, NY: Springer New York, 2016. http://dx.doi.org/10.1007/978-1-4939-3389-1_34.
Повний текст джерелаNosanchuk, Joshua Daniel, and Allan Jefferson Guimarães. "Histoplasma capsulatum Chaperonin 60: A Novel Adhesin and Vaccine Candidate." In Heat Shock Proteins, 189–202. Dordrecht: Springer Netherlands, 2013. http://dx.doi.org/10.1007/978-94-007-6787-4_12.
Повний текст джерелаDobrica, Mihaela-Olivia, Catalin Lazar, and Norica Branza-Nichita. "Production of Chimeric Hepatitis B Virus Surface Antigens in Mammalian Cells." In Vaccine Delivery Technology, 83–94. New York, NY: Springer US, 2020. http://dx.doi.org/10.1007/978-1-0716-0795-4_7.
Повний текст джерелаHara, Yuka, and Sheila Nathan. "Outer Membrane Proteins as Potential Candidate Vaccine Targets." In Post-genomic Approaches in Drug and Vaccine Development, 277–322. New York: River Publishers, 2022. http://dx.doi.org/10.1201/9781003339090-11.
Повний текст джерелаStreatfield, Stephen J., Natasha Kushnir, and Vidadi Yusibov. "Plant-Produced Recombinant Transmission Blocking Vaccine Candidates to Combat Malaria." In Commercial Plant-Produced Recombinant Protein Products, 103–33. Berlin, Heidelberg: Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-662-43836-7_7.
Повний текст джерелаGanguly, Bhaskar. "Computational Mining and Characterization of Hypothetical Proteins of Mycobacterium bovis Toward the Identification of Probable Vaccine Candidates." In Vaccine Design, 449–55. New York, NY: Springer US, 2021. http://dx.doi.org/10.1007/978-1-0716-1892-9_24.
Повний текст джерелаDhillon, Bhavjinder K., Nancy Y. Yu, and Fiona S. L. Brinkman. "Computational Prediction of Protein Subcellular Localization, Genomic Islands, and Virulence to Aid Antigen Discovery." In Immunomic Discovery of Adjuvants and Candidate Subunit Vaccines, 105–15. New York, NY: Springer New York, 2012. http://dx.doi.org/10.1007/978-1-4614-5070-2_6.
Повний текст джерелаТези доповідей конференцій з теми "Vaccine candidate protein"
Priyoatmojo, Dadang, Tri Handayani, Afi Candra Trinugraha, Teguh Wahyono, and Nina Herlina. "Soy Protein Isolate (SPI) Based Delivery System as Promising Mastitis Vaccine Carrier Candidate." In International Conference on Improving Tropical Animal Production for Food Security (ITAPS 2021). Paris, France: Atlantis Press, 2022. http://dx.doi.org/10.2991/absr.k.220309.035.
Повний текст джерелаIlmiya, Istifadatul, Hening Ryan Aryani, Nur Rohmah Prihatanti, Dwi Yuni Nur Hidayati, and Noorhamdani Noorhamdani. "Identification of hemagglutinin protein from Streptococcus agalactiae pili in mice erythrocytes as a vaccine candidate." In INTERNATIONAL CONFERENCE ON LIFE SCIENCES AND TECHNOLOGY (ICoLiST 2020). AIP Publishing, 2021. http://dx.doi.org/10.1063/5.0052701.
Повний текст джерелаSuryani, Yani, and Opik Taupiqurrohman. "Study of Immunoinformatics On E2 Protein of Type 16 HPV to Predict Cervical Cancer Peptide Vaccine Candidate." In Proceedings of the 1st International Conference on Islam, Science and Technology, ICONISTECH 2019, 11-12 July 2019, Bandung, Indonesia. EAI, 2020. http://dx.doi.org/10.4108/eai.11-7-2019.2298068.
Повний текст джерелаHossain, Farzana, and A. S. M. Rubayet-Ul-Alam. "Evolutionary analysis and prediction of peptide vaccine candidates for Nipah virus fusion protein." In 2016 International Conference on Medical Engineering, Health Informatics and Technology (MediTec). IEEE, 2016. http://dx.doi.org/10.1109/meditec.2016.7835376.
Повний текст джерелаGuimarães, Rosane, Andrea Silva, Luciane Gaspar, Marisol Simões, Patrícia Neves, Gisela Trindade, and Renato Marchevsky. "Immunization with recombinant, plant-produced yellow fever virus envelope (E) protein vaccine candidates in rhesus macaques." In I Seminário Anual Científico e Tecnológico em Imunobiológicos. Instituto de Tecnologia em Imunobiológicos, 2013. http://dx.doi.org/10.35259/isi.sact.2013_27301.
Повний текст джерелаSilva, Saulo Brivaldo Mendonça da, Ana Bárbara Xavier da Silva, Mariana Souza Bezerra Cavalcanti, João Lucas Pessoa de Vasconcelos, Maria Clara Cavalcante Gomes, and Nathaly Bruna de Oliveira Silva. "A PROTEÍNA PfGARP COMO POSSÍVEL CANDIDATA À VACINA ANTIMALÁRICA." In XXVII Semana de Biomedicina Inovação e Ciência. Editora IME, 2021. http://dx.doi.org/10.51161/9786588884119/28.
Повний текст джерелаYanuhar, Uun, Muhammad Musa, Diana Arfiati, Nico Rahman Caesar, and Nur Sakinah Junirahma. "In-vivo Test of Chlorella Protein Fragments as Nucleotide Vaccine Candidates in Grouper Viral Nervous Necrosis (VNN) Infection against Haematological Response." In 6th ICAMBBE (International Conference on Advance Molecular Bioscience & Biomedical Engineering) 2019. SCITEPRESS - Science and Technology Publications, 2019. http://dx.doi.org/10.5220/0009588100790083.
Повний текст джерелаRabbani, Naila, Paul John Thornalley, Maryam Al-Motawa, and Mingzhan Xue. "Vulnerabilities of the SARS-Cov-2 Virus to Proteotoxicity – Opportunity for Repurposed Chemotherapy of COVID-19 Infection." In Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2020. http://dx.doi.org/10.29117/quarfe.2020.0291.
Повний текст джерелаЗвіти організацій з теми "Vaccine candidate protein"
Bercovier, Herve, Raul Barletta, and Shlomo Sela. Characterization and Immunogenicity of Mycobacterium paratuberculosis Secreted and Cellular Proteins. United States Department of Agriculture, January 1996. http://dx.doi.org/10.32747/1996.7573078.bard.
Повний текст джерелаMcElwain, Terry F., Eugene Pipano, Guy H. Palmer, Varda Shkap, Stephn A. Hines, and Wendy C. Brown. Protection of Cattle against Babesiosis: Immunization against Babesia bovis with an Optimized RAP-1/Apical Complex Construct. United States Department of Agriculture, September 1999. http://dx.doi.org/10.32747/1999.7573063.bard.
Повний текст джерелаSordillo, Lorraine, Don Wojchowski, Gary Perdew, Arthur Saran, and Gabriel Leitner. Identification of Staphylococcus aureaus Virulence Factors Associated with Bovine Mastitis. United States Department of Agriculture, February 2001. http://dx.doi.org/10.32747/2001.7574340.bard.
Повний текст джерела